Cortexin vs Cerebrolysin
Comparing two brain-derived peptide preparations used in Russia and Eastern Europe for neurological conditions.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Cortexin
Dossier overview
Cerebrolysin
Dossier overview
Overview
Cortexin and Cerebrolysin are both brain-derived peptide preparations used in Russia and Eastern Europe for various neurological conditions. Cerebrolysin is derived from pig brain, while Cortexin is derived from cattle cerebral cortex. Neither is FDA-approved, and Western evidence is limited.
Key Facts
| Aspect | Cortexin | Cerebrolysin |
|---|---|---|
| Source | Bovine cerebral cortex | Porcine brain |
| Composition | Peptide mixture | Peptide mixture |
| Type | Complex biological | Complex biological |
| Approval | Russia | Russia, Europe (some) |
| FDA Status | Not approved | Not approved |
Composition Comparison
| Component | Cortexin | Cerebrolysin |
|---|---|---|
| Peptide Content | Low-molecular-weight peptides | ~25% peptides, amino acids |
| Source Tissue | Cerebral cortex (cattle) | Whole brain (pig) |
| Active Components | Poorly characterized | Contains BDNF, CNTF, others |
| Standardization | Limited | Some characterization |
What Are These Preparations?
Both are:
- Extracts from animal brain tissue
- Complex mixtures of peptides and amino acids
- Not single defined molecules
- Difficult to fully characterize
- Used historically in Eastern Europe
Mechanism (Proposed)
| Mechanism | Cortexin | Cerebrolysin |
|---|---|---|
| Neurotrophic Support | Claimed | Claimed |
| Antioxidant | Claimed | Claimed |
| Neuroprotection | Claimed | Claimed, some evidence |
| Specific Targets | Not defined | BDNF-like activity |
Evidence Comparison
| Aspect | Cortexin | Cerebrolysin |
|---|---|---|
| Human Trials | Russian studies | Multiple (including Western) |
| Cochrane Reviews | Not reviewed | Mixed conclusions |
| Western Publications | Very few | More extensive |
| Quality of Evidence | Low | Low-Moderate |
Cerebrolysin Evidence
Cerebrolysin has more Western research:
- Stroke trials (mixed results)
- Alzheimer’s trials (modest effects)
- TBI studies (some positive signals)
- Cochrane reviews: insufficient evidence
Cortexin Evidence
Cortexin has less international research:
- Primarily Russian publications
- Pediatric neurological conditions
- Stroke recovery
- Lower publication standards often
Clinical Applications (Where Approved)
Cortexin Uses (Russia)
| Indication | Evidence |
|---|---|
| Pediatric neurology | Russian data |
| Stroke recovery | Russian data |
| TBI | Russian data |
| Cognitive impairment | Russian data |
Cerebrolysin Uses
| Indication | Evidence |
|---|---|
| Stroke | Multiple trials, mixed |
| Alzheimer’s disease | Some trials |
| TBI | Some positive data |
| Dementia | Limited |
Administration
| Aspect | Cortexin | Cerebrolysin |
|---|---|---|
| Route | IM (intramuscular) | IV or IM |
| Course Duration | 10-20 days | 10-30 days |
Safety Profile
Cortexin
| Aspect | Information |
|---|---|
| Common Effects | Injection site reactions |
| Serious Concerns | Prion disease (theoretical - bovine) |
| Drug Interactions | Not well characterized |
| Long-term Safety | Not established |
Cerebrolysin
| Aspect | Information |
|---|---|
| Common Effects | Injection site, dizziness |
| Serious Concerns | Prion disease (theoretical - porcine) |
| Drug Interactions | Some data |
| Long-term Safety | More data than Cortexin |
Prion Disease Concern
Both are animal brain-derived:
- Theoretical risk of prion transmission
- Manufacturing processes claim to eliminate risk
- No documented cases linked to these products
- Regulatory bodies in some countries accept safety
Regulatory Status
| Aspect | Cortexin | Cerebrolysin |
|---|---|---|
| Russia | Approved | Approved |
| EU | Not approved | Some countries |
| US (FDA) | Not approved | Not approved |
| Manufacturing | Russia | Austria (EVER Pharma) |
Quality Considerations
| Factor | Cortexin | Cerebrolysin |
|---|---|---|
| Manufacturer | Russian | Austrian/Western |
| GMP Standards | Russian GMP | EU GMP |
| Batch Consistency | Variable | More standardized |
| International Access | Limited | More available |
Key Differences
| Factor | Cortexin | Cerebrolysin |
|---|---|---|
| Source | Bovine cortex | Porcine brain |
| Research Base | Russian primarily | More international |
| Manufacturing | Russian | Western |
| Quality Control | Lower | Higher |
| Western Evidence | Minimal | Some |
| Administration | IM only | IV or IM |
Summary
- Both are brain-derived peptide preparations with limited Western evidence
- Cerebrolysin has more international research and Western manufacturing standards
- Cortexin is primarily researched/manufactured in Russia with less international data
- Neither is FDA-approved; evidence remains insufficient by Western standards
- Theoretical prion concerns exist for both (animal brain-derived)
- Cerebrolysin has been more extensively evaluated in Western trials (though results are mixed)
- Quality and standardization favor Cerebrolysin
This comparison is for educational purposes only. Neither preparation is FDA-approved. Evidence from Western clinical trials remains insufficient for most claimed indications. Consult a healthcare provider for medical decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.